IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v16y2019i23p4589-d288844.html
   My bibliography  Save this article

Pyruvate Kinase M2 Expression: A Potential Metabolic Biomarker to Differentiate Endometrial Precancer and Cancer that is Associated with Poor Outcomes in Endometrial Carcinoma

Author

Listed:
  • Yu-Ju Lai

    (Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
    Department of Obstetrics and Gynecology, Tri-Service General Hospital, Magong City 88056, Penghu Branch, Taiwan)

  • Yu-Ching Chou

    (School of Public Health, National Defense Medical Center, Taipei 114, Taiwan)

  • Yi-Jia Lin

    (Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan)

  • Mu-Hsien Yu

    (Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan)

  • Yu-Che Ou

    (Department of Obstetrics and Gynecology, Chiayi Chang Gung Memorial Hospital, Chiayi 600, Taiwan
    Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 800, Taiwan)

  • Po-Wei Chu

    (Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan)

  • Chia-Chun Wu

    (Department of Orthopedics, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan)

  • Yu-Chi Wang

    (Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
    These authors contributed equally to this work.)

  • Tai-Kuang Chao

    (Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
    These authors contributed equally to this work.)

Abstract

Background: Pyruvate kinase M2 (PKM2) is a regulator of the processes of glycolysis and oxidative phosphorylation, but the roles that it plays in endometrial cancer remain largely unknown. This study evaluated the PKM2 expression in normal endometrium, endometrial hyperplasia, and endometrial carcinoma, and its prognostic value was investigated in endometrial carcinoma patients. Methods: A hospital-based retrospective review was conducted to examine the immunohistochemical PKM2 distribution in 206 endometrium samples from biopsies or hysterectomies. The immunoreactivity of PKM2 was divided into groups of low and high scores according to the extent and intensity of staining. Results: Intense cytoplasmic staining was observed for the PKM2 protein in malignant endometrial lesions. A high PKM2 score was observed in many endometrial carcinoma samples (50.0%), but there was a low percentage in endometrial atypical hyperplasia (12.5%). High PKM2 expression was not found in the normal endometrium (0.0%) nor endometrial hyperplasia without atypia (0.0%). The PKM2 protein score was significantly higher in endometrial carcinoma samples than premalignant endometrial lesions ( p < 0.001). Notably, higher PKM2 scores in cases of endometrial carcinoma correlated with poor overall survival ( p = 0.006), and the hazard ratio for death was 3.40 (95% confidence interval, 1.35–8.56). Conclusions: Our results indicate that the prevalence of PKM2 high tumor cells in endometrial carcinoma is significantly associated with worse prognostic factors and favors a poor prognosis. The expression of PKM2 is also a potential histopathological biomarker for use in the differential diagnosis of malignant and premalignant endometrial lesions.

Suggested Citation

  • Yu-Ju Lai & Yu-Ching Chou & Yi-Jia Lin & Mu-Hsien Yu & Yu-Che Ou & Po-Wei Chu & Chia-Chun Wu & Yu-Chi Wang & Tai-Kuang Chao, 2019. "Pyruvate Kinase M2 Expression: A Potential Metabolic Biomarker to Differentiate Endometrial Precancer and Cancer that is Associated with Poor Outcomes in Endometrial Carcinoma," IJERPH, MDPI, vol. 16(23), pages 1-10, November.
    • Handle: RePEc:gam:jijerp:v:16:y:2019:i:23:p:4589-:d:288844
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/16/23/4589/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/16/23/4589/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Heather R. Christofk & Matthew G. Vander Heiden & Ning Wu & John M. Asara & Lewis C. Cantley, 2008. "Pyruvate kinase M2 is a phosphotyrosine-binding protein," Nature, Nature, vol. 452(7184), pages 181-186, March.
    2. Heather R. Christofk & Matthew G. Vander Heiden & Marian H. Harris & Arvind Ramanathan & Robert E. Gerszten & Ru Wei & Mark D. Fleming & Stuart L. Schreiber & Lewis C. Cantley, 2008. "The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth," Nature, Nature, vol. 452(7184), pages 230-233, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Hanna Kjellin & Henrik Johansson & Anders Höög & Janne Lehtiö & Per-Johan Jakobsson & Magnus Kjellman, 2014. "Differentially Expressed Proteins in Malignant and Benign Adrenocortical Tumors," PLOS ONE, Public Library of Science, vol. 9(2), pages 1-10, February.
    2. Shiwen Wang & Bowen Jiang & Tengfei Zhang & Lixia Liu & Yi Wang & Yiping Wang & Xiufei Chen & Huaipeng Lin & Lisha Zhou & Yukun Xia & Leilei Chen & Chen Yang & Yue Xiong & Dan Ye & Kun-Liang Guan, 2015. "Insulin and mTOR Pathway Regulate HDAC3-Mediated Deacetylation and Activation of PGK1," PLOS Biology, Public Library of Science, vol. 13(9), pages 1-27, September.

    More about this item

    Keywords

    pyruvate kinase M2; endometrial hyperplasia; endometrial carcinoma;
    All these keywords.

    JEL classification:

    • M2 - Business Administration and Business Economics; Marketing; Accounting; Personnel Economics - - Business Economics

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:16:y:2019:i:23:p:4589-:d:288844. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.